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Hereditary cerebellar ataxias are a wide group of pro-
gressive, degenerative diseases, which manifest as lack of
control and coordination of voluntary movements due
to progressive loss of Purkinje cells and other cell types
in the cerebellum. Cerebellar degeneration could affect
people of any age, is often diagnosed after symptoms
start to manifest and no prevention and no causal and
really effective therapy is available today.
There is high variability in pathogenesis in human cer-
ebellar degenerations and high variability in onset and
progress of the disease. Though the basal manifestation
of all cerebellar degenerations is similar as it is related
to dysfunction of the cerebellum, there are some differ-
ences between individual types of them and also some
variability in the frame of one disease making the clini-
cal diagnosis difficult. The manifestation of the mutation
could be also modified by the genetic background. For
all of that, individual approach of treatment is necessary.
There is a vide spectrum of mouse models of geneti-
cally determined cerebellar degenerations including both
spontaneous mutants and transgenic mice, some of
which are available in several mouse strains. This situa-
tion is analogous to variability of human hereditary cer-
ebellar disorders and genetic heterogeneity of human
population. Mouse models can be used for investigation
of efficiency of experimental therapy in individual types
of cerebellar degenerations and for studying of the effect
of genetic background on the pathological process. Such
research could allow identifying factors determining pro-
gress of the disease and influencing the effect of the
therapy. This is necessary to choose the optimal treat-
ment for each individual patient and for development of
new therapeutic methods.
One of therapies which could benefit from such research
is stem cell and neurotransplantation therapy. So far it
seems promising in slowing down progress, but it might
even mitigate neurological deficit caused by the cerebellar
degeneration.
Nevertheless, as experiments in mice shoved differ-
ent types of grafts have different effects. For example
mesenchymal stem cells prevent neurodegeneration pro-
gression, but do not reverse already developed cell loss
and neurological deficit. Transplanted suspension of
embryonic cerebellar cells generates new graft-derived
Purkinje cells in Purkinje cell degeneration mice and
improvement of motor function was described in them.
On the other hand, in Lurcher mice functional benefit of
cerebellar tissue transplantation has not been achieved yet.
In addition, cultivated embryonic neural stem cells survive
well in the host cerebellum and despite they do not create
any new Purkinje cells they have been shown to rescue
Purkinje cells in a mouse model of Niemann-Pick disease.
Genetically defined mouse strains with different muta-
tions causing neurodegenerative diseases and different
mouse strain backgrounds for the same mutations and
analysis of their genome and proteome would be valuable
tool to identify genetic markers and factors important for
assessment of prognosis and management of appropriate
stem-cell therapy and for development of new therapeutic
approaches based on the principles of personalized
medicine.
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